Emphysema and lung cancer risk

2024-8-1

Are PD-1T TILs merely an expensive and unuseful whim as biomarker?

2024-8-1

Redefining YAP1 in small cell lung cancer: shifting from a dominant subtype marker to a favorable prognostic indicator

2024-8-1

Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer

2024-8-1

Single-center clinical experience of extended sleeve lobectomy (ESL) versus standard sleeve lobectomy (SL)

2024-8-1

Identifying genetically-supported drug repurposing targets for non-small cell lung cancer through mendelian randomization of the druggable genome

2024-8-1

Oncogene-addicted solid tumors and microbiome—lung cancer as a main character: a narrative review

2024-8-1

Clinical insights: five-year follow-up of KEYNOTE-189 trial outcomes and more

2024-8-1

Breaking barriers: patient-derived xenograft (PDX) models in lung cancer drug development—are we close to the finish line?

2024-8-1

Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-naïve advanced ALK-positive non-small cell lung cancer: a systematic review and network meta-analysis

2024-8-1

Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study

2024-8-1

CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study

2024-8-1

Prognostic role of dynamic changes in inflammatory indicators in patients with non-small cell lung cancer treated with immune checkpoint inhibitors—a retrospective cohort study

2024-8-1

Effective induction immunotherapy minimizes surgical invasiveness for locally advanced lung cancer

2024-8-1

Knowledge and beliefs about lung cancer screening among Black individuals at high risk: a qualitative approach

2024-8-1

Neutrophil estimation and prognosis analysis based on existing lung squamous cell carcinoma datasets: the development and validation of a prognosis prediction model

2024-8-1

Enhanced tumor targeting and penetration of fluorophores via iRGD peptide conjugation: a strategy for the precision targeting of lung cancer

2024-8-1

Assessing the transportability of radiomic models for lung cancer diagnosis: commercial vs. open-source feature extractors

2024-8-1

Effect of family history of cancer on postoperative survival in patients with non-small cell lung cancer

2024-8-1

Can a dysfunctional T-cell gene signature predict nonresponse to PD-1 blockade in non-small cell lung cancer?

2024-8-1

The (un)lucky seven—how can we mitigate risk factors for postoperative pneumonia after lung resections?

2024-8-1

REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?

2024-8-1

A nomogram predicting the risk of extrathoracic metastasis at initial diagnosis of T≤3cmN0 lung cancer

2024-8-1

CT-based radiomic consensus clustering association with tumor biological behavior in clinical stage IA adenocarcinoma: a retrospective study

2024-8-1

Successful carinal reconstruction with right main bronchial flap rotational embedded augmentation: a case report

2024-8-1

Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review

2024-8-1

Prognostic and predictive significance of soluble programmed death ligand 1 in bronchoalveolar lavage fluid in stage IV non-small cell lung cancer

2024-8-1

LungPath: artificial intelligence-driven histologic pattern recognition for improved diagnosis of early-stage invasive lung adenocarcinoma

2024-8-1

Efficacy and prognostic factors of stereotactic body radiotherapy combined with immunotherapy for pulmonary oligometastases: a preliminary retrospective cohort study

2024-8-1

Immune-related osteoblastic bone alterations mimicking bone metastasis in a small-cell lung cancer patient treated with durvalumab: a case report

2024-8-1

Radiogenomics models for predicting prognosis in locally advanced non-small cell lung cancer patients undergoing definitive chemoradiotherapy

2024-8-1

Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space

2024-8-1

Age at first sexual intercourse, age at menarche, and age at menopause: a mendelian randomization study on lung cancer risk

2024-7-1

Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer

2024-7-1

Timing of stereotactic radiosurgery within the first-line systemic treatment in non-small cell lung cancer brain metastases: a retrospective single-center cohort study

2024-7-1

Resected lung adenocarcinoma with lymph node metastasis: is ground glass opacity component a prognostic factor?

2024-7-1

Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centers

2024-7-1

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study

2024-7-1

PD-L1 expression in non-small cell lung carcinoma in Latin America: a systematic review and meta-analysis

2024-7-1

Tumor cavitation in patients with non-small-cell lung cancer receiving anti-angiogenic therapy with apatinib

2024-7-1

Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases

2024-7-1

Association between thymus density loss and efficacy in non-small cell lung cancer patients treated with immune checkpoint inhibitors

2024-7-1

PD-L1 expression from surgically resected lung tumors predictive of early progression in patients previously treated with targeted therapy for initially unresectable non-small cell lung cancer

2024-7-1

Immunohistochemistry identifies E-cadherin, N-cadherin and focal adhesion kinase (FAK) as predictors of stage I non-small cell lung carcinoma spread through the air spaces (STAS), and the combinations as prognostic factors

2024-7-1

Association between strenuous sports or other exercises and lung cancer risk: a mendelian randomization study

2024-6-1

Predictive value of delta-radiomic features for prognosis of advanced non-small cell lung cancer patients undergoing immune checkpoint inhibitor therapy

2024-6-1

The APPLE trial in the evolving landscape of ctDNA monitoring

2024-6-1

Bioinformatics analysis of an immunotherapy responsiveness- related gene signature in predicting lung adenocarcinoma prognosis

2024-6-1

Clinical impact of EGFR and KRAS mutations in surgically treated unifocal and multifocal lung adenocarcinoma

2024-6-1

Radical resection in a patient with stage IIIA non-small cell lung cancer with the EGFR exon 19 deletion mutation after neoadjuvant targeted therapy with osimertinib: a case report

2024-6-1